Aims: This review explores the balance between the incremental data supplied by stress echocardiography and its cost. This technique is now established as an accurate tool for the diagnosis of coronary artery disease and myocardial viability, but the current medical-economic environment mandates careful consideration of the impact of the results on patient outcomes.
Introduction
Recent developments in imaging technology have improved the accuracy of stress testing approaches for the diagnosis and prognostic assessment of coronary disease. However, each new development has produced relatively minor increments of diagnostic or prognostic information at major increments of cost (Fig. 1) . Enormous numbers of stress and stress imaging studies are performed, at significant cost ( Table 1 ). The current medical economic environment dictates that this expenditure should improve patient outcomes, or at least avoid other expense.
Studies of cost-effectiveness are based on the concept that where multiple interventions are shown to improve the prognosis of various diseases, choices between them may be based on their efficacy for improving outcome, balanced by cost. However, the comparison of investigative approaches is quite unlike that of treatment strategies, and presents some difficulties for analysis of cost-effectiveness. First, the connection between testing and improvement of prognosis is less direct than for treatment strategies. Second, assessment of the clinical value of various investigative techniques has focused on the diagnosis of coronary disease, with relatively fewer data regarding the prediction of prognosis. In this respect, an important distinction needs to be made between the diagnosis of significant stenoses and the prediction of outcome, given that myocardial infarction is frequently provoked by rupture of a coronary plaque of only mild to moderate severity. Third, it is difficult to estimate the dollar cost per quality of life year gained on the basis of the published literature. This is very important, because of the substantial cost of diagnostic tests, particularly imaging protocols, for coronary disease.
Despite the limitations mentioned, several lines of data justifying the cost-efficient use of stress testing for patient management will be discussed in this review. A substantial body of data has been obtained which justifies the avoidance of testing in some patient groups, according to Bayes' theorem. Second, some comparative data have been presented between diagnostic tests that justify the use of imaging rather than non-imaging approaches, based on the balance between efficacy for the diagnosis of coronary disease and the cost of reaching that diagnosis. Finally, some prospective studies have compared the cost and outcomes of invasive and non-invasive diagnostic strategies for coronary disease, keeping in mind that the performance of angiography is likely to provoke interventions that may or may not be necessary. Initially, however, we should review how cost and outcomes are defined.
How to Analyse the Balance Between Cost and Outcomes
Several approaches may be used in order to balance cost and outcomes [1] . The simplest exercise is cost minimization, but this is only applicable when the tests are exactly comparable and have the same outcome. Cost-effectiveness analysis may be applied when the nature of the tests are similar, but their costs and outcomes are different -this corresponds to the tests used to evaluate coronary disease. Cost utility is probably a measure of more interest to public health and medical insurance. In this analysis, comparable outcomes of different nature might be compared (e.g. the decision to screen for cancer versus heart disease, or the outcome of a new coronary intervention versus an expensive intervention for another condition such as dialysis). Finally, cost benefit analysis may be performed when all costs and outcomes can be measured in monetary terms, but given the difficulties of expressing human life or life quality in these terms, such analyses are difficult.
Neither cost nor effectiveness are easy to measure. The most widely available index of cost is charges, but these are variable, and determined by the market [2] . As most insurance companies and government authorities have been quite effective in controlling expenditure, reimbursement is often used as a surrogate for cost. Although this is inexact, this approach has the benefit of being relatively consistent between centres within the same region. More difficult to gauge is the true cost of performing an investigation, which comprises variable costs (e.g. consumables), stepped costs (e.g. salaries), fixed costs (capital cost of equipment, service, depreciation), as well as induced cost, reflecting the additional cost of complications.
Effectiveness has been most widely evaluated by defining cardiac endpoints [3] . Cardiovascular mortality is probably the most important parameter, but particularly when stable chronic coronary disease is being evaluated, the incidence of cardiac death is low. Smaller studies have therefore often included 'soft' events such as infarction, unstable angina and admissions for heart failure. Although from an economic standpoint these endpoints are an important source of additional health care expenditure, their definition may be variable between studies, and given the role of thrombus in provoking acute coronary syndromes, these events may defy prediction. Although still looked upon as a soft endpoint, quality of life (which may be expressed by a vast number of general and disease-specific indices) is an important parameter that is often neglected. Quality of life and survival may be expressed together as QALY, reflecting the number of life years saved by a procedure multiplied by the fraction of normal life quality [4] . Finally, most reported investigations have addressed the efficacy of stress ECG or stress imaging protocols (reflecting whether they are able to work for predicted purposes), and few have dealt with effectiveness (reflecting their ability to work in routine practice). Nonetheless, despite these limitations, a substantial literature has accumulated regarding the prognostic value of stress echocardiography.
Balancing Diagnostic Accuracy and Cost

Efficient Patient Selection (or 'Who should not Have a Stress Test')
A pivotal distinction in the approach to diagnostic testing for coronary disease is between a deterministic and a probabilistic approach to the results of testing. A deterministic approach would suggest that patients with a positive test necessarily have coronary disease, and those with the negative test do not. Clearly, none of the tests used have a sufficient level of accuracy to justify this approach, even though conceptually some clinicians may be guilty of this interpretation. The probabilistic approach is based on the likelihood of coronary disease being increased or decreased by the finding of a positive or negative test. This inherently invokes Bayes theorem, which states that the probability of disease being present following a positive or negative test is dependent upon the probability of disease on clinical grounds [5] . Figure 2 illustrates the interaction between pre-and post-test probability for an inaccurate and an accurate diagnostic test. The degree of deviation from the line of identity is determined by test accuracy; if the test is so inaccurate as to present no useful data, the post-test probability will exactly parallel the pre-test probability. However, at the extremes of pre-test probability, the impact of positive and negative test results is relatively less. Even using the best available tests, if a patient is unlikely to have coronary disease on clinical grounds, they remain unlikely to have coronary disease even if the test result is positive; in this situation, a positive test result most likely reflects a false positive. Conversely, data provided by stress testing of patients at very high probability of coronary disease are also unreliable.
The pre-test probability of coronary disease may be defined and quantified on clinical grounds, using various scoring systems. The simplest algorithm was defined by Diamond and Forrester [5] , and defines pre-test probability on the basis of age, gender, and the nature of cardiac symptoms. Coronary risk factors are not integrated into the model, but have been added in studies reported by the group at Duke University [6] , as well as a simpler score developed by Morise [7] . Rather than examining the probability of anatomic coronary disease, the Framingham data have been used to establish a clinical risk index that identifies the probability of adverse outcome on the basis of clinical presentation [8] . The application of probability theory to the diagnosis of coronary disease justifies the use of non-invasive testing in patients at intermediate probability of coronary disease on clinical grounds. Testing is unlikely to justify its cost for diagnostic purposes in patients at either very low or very high probability of disease. Nonetheless, this does not mean that testing should never be performed in these patient groups, as it may be used for example to assess the functional severity of coronary stenoses, or to identify myocardial viability.
Selection of Exercise and Imaging Tests
A wide spectrum of diagnostic tests, involving a combination of some form of stress protocol with various diagnostic approaches for ischemia, has been applied to the diagnosis of coronary artery disease, at various levels of cost (Table 1 ). The simplest approach to analysis of cost-effectiveness is to examine the cost implications of various diagnostic regimens, and their diagnostic performance. Such analyses are based upon comparisons of test results with coronary angiography, recognizing that use of the latter to define the presence or absence of coronary disease is itself very problematic. Even when there are no imaging limitations (e.g. eccentric stenoses, hazy areas due to thrombus), the relationship between stenosis severity and physiological reduction of coronary flow is quite variable. Under conditions of maximal coronary hyperaemia, flow may remain normal in some segments with stenosis severity of 50-70% [9, 10] . Moreover, predictive values are dependent on pre-test probability of coronary disease, as well as post-test referral bias [11] . The standard exercise test has the benefit of huge clinical experience [12] and is substantially less costly than . Low pre-test probability (<20%) might be characterized by atypical chest pain in a young patient (<40 years old).
Intermediate pre-test probability (20-80%) is characterized by atypical chest pain in a middle aged man (>40 years old) or older women (>50 years old). High pre-test probability (>80%) might be characterized by typical angina in an older man (<60 years old).
the stress imaging approaches. Despite these attractions, patients must satisfy two criteria in order for useful data to be obtained from this investigation. First, the patient must be able to exercise maximally. Inability to exercise, or submaximal exercise (categories that account for about 40% of patients presenting to a stress laboratory) mandate pharmacological stress testing, because the ECG is insensitive for coronary disease during pharmacological stress, probably reflecting the relatively low work loads on the heart induced by these stressors [13] . Second, the resting electrocardiogram must permit a diagnostic evaluation of repolarization changes induced by ischemia. Of the patients who are able to exercise, approximately one half have a non-diagnostic ECG, and these must undergo an imaging test. Thus, despite the relatively high cost of imaging procedures, there is no alternative but to apply them if stress testing is required for diagnosis in patients who cannot exercise adequately, or who have a non-diagnostic ECG.
Accuracy of Different Stress Techniques Accuracy of Individual Tests
A large body of data have been obtained to define the accuracy of various stress testing approaches for the diagnosis of coronary disease. Table 2 lists the sensitivity and specificity of a number of stress testing strategies, derived from meta-analyses of published studies [14] [15] [16] [17] .
Use of Imaging Tests Instead of the Exercise ECG
An imaging test is always indicated in preference to the stress ECG if the patient is unable to exercise or has non-diagnostic ECG. A more difficult decision is when the patient can exercise maximally and has an interpretable ECG -in this situation, conventional teaching is that the exercise ECG should be the first test performed, but the physician may feel ambivalent about this, as stress imaging tests are more accurate. The differences in accuracy can be minimized by consideration of subgroups who 'should' undergo an exercise ECG (i.e. able to exercise, interpretable ECG), but among whom the test is less reliable. The first such group are women, among whom false-positive and false-negative responses are quite prevalent [18] . On the basis of comparative data, it is clear that stress echocardiography is significantly more specific than stress ECG testing [19] . On the basis of comparative data, it is clear that stress echocardiography is significantly more specific than stress ECG testing [19] . The cost implications of using stress echocardiography in this group are discussed in the next section. Similarly, patients with left ventricular hypertrophy very commonly have false-positive exercise test results. The resting electrocardiogram is a very insensitive indicator of the presence of left ventricular hypertrophy, and patients who are likely to have LVH are better studied using stress echocardiography than the stress ECG [20] .
Selection of Echocardiography Versus Nuclear Imaging
Comparisons between the techniques have shown similar levels of overall accuracy. The nuclear techniques are somewhat more sensitive, making them more attractive for decision-making regarding the physiological significance of coronary stenoses. On the other hand, the exercise echocardiogram is more specific, particularly in the setting of left ventricular hypertrophy [21] , and left bundle branch block, which are both problematic for the nuclear tests. In fact, on the basis of computer modelling [22] , it has been recommended that the stress echocardiogram be focused upon patients in the low-tointermediate range of pre-test probability, while the nuclear approach should be focused upon those at intermediate to higher levels of pre-test probability. This approach maximizes the benefit of greater specificity of exercise echocardiography, and the higher sensitivity of nuclear imaging. The most critical observation is that both techniques are dependent upon an expert observer, and local expertise should be the dominant factor in deciding which test is used.
Computer Models for Balancing Cost and Accuracy
The simplest models of cost controls with functional testing have purely examined the relationship between the number of diagnoses missed and the total cost of testing, incorporating both the stress test and the subsequent angiography. These simple models assume that all patients with a positive test (or test sequence) proceed to angiography. Such an analysis has been applied to the comparison between stress echo and stress ECG results in women, taking into account a group with 37% Table 2 . Sensitivity and specificity of stress testing techniques for the diagnosis of coronary artery disease from meta-analyses [10] [11] [12] [13] . Modality Patient (no of studies) Sensitivity Specificity
Exercise ECG [14] 24 074 (147 studies) 68% 77% Exercise echo [16] 3456 (24 studies) 85% 77% Exercise SPECT [15] 3237 (27 studies) 87% 64% Dipyridamole SPECT [15] 1272 87% 81% Dipyridamole PET [15] 507 94% 83%
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Eur J Echocardiography, Vol. prevalence of coronary artery disease and the comparative sensitivity and specificity of the two tests [19] . Cost analyses have been based on Medicare reimbursement levels in 1994 of $63 for an exercise ECG, $246 for an exercise echo, and $1424 for coronary angiography. The proportion of patients proceeding to angiography, the rate of inappropriate angiography, false negative rate and cost of common strategies are summarized in Table  3 . The use of an initial imaging strategy is associated with similar accuracy to use of the stress ECG, as the greater total cost is offset by lower rates of angiography. A similar analysis has been performed in patients with known or suspected left ventricular hypertrophy, showing that an imaging test to begin with causes fewer false positive stress tests, and therefore reduces the angiography rate [20] . The models in the previous paragraph balance the total cost of investigation with the number of patients in whom coronary disease is missed. More sophisticated models have been developed by the group at Emory University [22] . These models are based upon the assumption that the diagnosis of coronary artery disease improves life expectancy at full life quality by 3 years over a 10-year follow-up. Cost analyses were performed based upon Medicare reimbursement for the original testing plus the induced costs of subsequent testing and the costs of complications. The respective sensitivity and specificity were assumed to be 70% and 70% for the exercise, ECG, 80% and 85% for exercise echo, 90% and 70% for SPECT, and almost complete accuracy was assumed for angiography. Taking into account only the cost of investigation, the most inexpensive test was exercise echocardiography, because its high specificity was responsible for sending fewer patients to angiography.
Conversely, taking into account the anticipated improvements in outcome, the most sensitive test for identifying coronary disease (angiography) was expected to save most lives. However, once these two pieces of data were combined (Table 4) an interesting pattern emerged. Individuals at low to intermediate probability of coronary disease (20-50%) were most efficiently studied by exercise echocardiography, because the proportion of patients likely to have a positive test (and therefore improved life expectancy) was relatively low, while cost was held down by angiography in fewer patients due to the high specificity of the test. Conversely, individuals at intermediate to high probability of disease (50-80%) were most efficiently studied by SPECT, because although costs were greater and more patients proceeded to angiography, the proportion of individuals with coronary disease (among whom diagnosis would convey an improvement of life expectancy) was greater. Finally, it is critical to remember that these data apply purely to the assumptions mentioned above. Very likely, the diagnosis of coronary disease does not add 3 years at full life quality, and the milder the abnormality (i.e. the less likely intervention would alter outcome), the less beneficial SPECT would prove. Conversely, the specificity of SPECT has almost certainly been improved by new technologies (e.g. gated SPECT), blunting the difference from stress echocardiography in patients at low risk of disease.
The EMPIRE study [23] sought to measure the costeffectiveness of four diagnostic strategies in 396 patients newly presenting with possible coronary artery disease, Table 3 . Cost and accuracy data developed from Monte Carlo stimulation of different diagnostic strategies for diagnosis of coronary disease in women [19] . Table 4 . Cost per quality of life years saved using different diagnostic strategies in patients with various pre-test probabilities of coronary artery disease. See text for assumptions about cost and quality of life years saved [22] . and to compare cost-effectiveness in matched European centres that routinely used and did not use myocardial perfusion imaging. Patients were followed up for 2 years in order to assess outcome; the numbers of soft and hard cardiac events over 2 years and final symptomatic status did not differ between strategy or centre. The cost, positive and negative predictive values of four strategies (exercise ECG proceeding to angiography, exercise ECG proceeding to SPECT and thence angiography, SPECT with angiography, and angiography alone) are summarized in Table 5 . In centres using a SPECT strategy compared with those which did not, cost was lower ($529 vs $667, P=0·006), sensitivity was greater (93 vs 88%, P=0·02), and specificities were comparable (79 vs 80%, P=ns). The total 2-year costs in those with coronary artery disease were similar ($5563 using SPECT vs $5428 in the rest), but SPECT reduced costs in those without disease ($623 vs $916, P=0·001). The prognostic power at diagnosis was higher (P<0·0001) and normal coronary angiography rate lower (P=0·07) in the scentigraphic strategies. Thus, investigative strategies using myocardial perfusion imaging are cheaper and equally effective when compared with strategies that do not use myocardial perfusion imaging.
Predicting Outcomes: Can Functional Testing Guide Therapy and Save Money?
Identification of Low Risk Patients
Myocardial SPECT imaging has been shown to be a powerful predictor of outcome in patients with coronary artery disease [24] [25] [26] . As stress echocardiography is a 'younger' technique, the prognostic data has lagged behind that published with SPECT. However, this situation is being redressed, and a number of studies (Table 6 ) involving large numbers of patients and significant follow-up have now been published for exercise of pharmacological stress echocardiography [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . The comparison of stress echocardiography and stress myocardial perfusion imaging [44] has been clouded by the use of different end-points in various studies as well as more limited echo than SPECT data, reflecting the comparative youth of the technique. In studies that have looked at death or hard events, the yearly event rate with a negative exercise or dobutamine echo was <1% per year. Moreover, the warranty of a negative test is at least 2 years. Later in follow-up, the cardiac events in individuals with a negative test probably reflects the presence of progressive coronary disease.
Ideally, we would like to have a test that was completely effective in predicting freedom from subsequent events. The predictors of events in individuals with a negative test include increasing age, low workload, anginal symptoms despite the absence of identifiable wall motion abnormalities, and left ventricular hypertrophy [30] . A score has been created to identify the likelihood of events despite the findings of a negative stress echo result.
Stratification of Risk in Patients with Positive Tests
Cardiac death is uncommon in individuals with stable chronic coronary disease. Although studies of SPECT have been of sufficient size and power to address the prediction of cardiac death, outcome studies of stress echocardiography have been smaller and powered mainly to examine composite endpoints. Although the presence of ischaemia, scar, or both, by either SPECT or stress echocardiography is clearly predictive of cardiac events, the predictive value of a positive test has generally been <20%. Risk is influenced by the level of clinical risk, the extent and severity of ischaemia and the extent of infarction, as well as the ischaemic threshold. Clinical factors have been shown to identify risk in patients with stable CAD quite effectively [6] , and the use of clinical scores to identify patients at the extremes of risk on clinical grounds may help to avoid inappropriate investigations. However, the impact of clinical risk status has been better evaluated in the nuclear literature Table 5 . Balance between costs and predictive values of diagnostic strategies in the EMPIRE study [23] . than with echocardiography [45] . The impact of clinical risk on the outcomes following SPECT is illustrated in Figure 3 . Irrespective of the degree of positivity of the scan in the low risk group, end-points are uncommon, and the prognostic value of studying such a group might be reasonably questioned. The presence of worse than mild defect extent in the intermediate and high risk group was more strongly associated with cardiac events.
The extent and severity of perfusion defects have been shown to correlate very well with the outcomes of patients studied using SPECT (Fig. 4) . The strongest predictor is the summed stress score, which reflects both the extent and severity of rest and stress perfusion defects. Limited data have indicated that the analogous wall motion score index is predictive of outcome using stress echocardiography [40] . The frequency of adverse outcomes in patients with mild fixed or reversible defects Table 6 . Use of stress echocardiography to predict events in patients with chronic stable coronary disease.
Stress n (pts) mean F/U PV+ test PV test Comments Sawada [27] Tml 148 28 -96% Negative tests Krivokapich [28] Tml 360 12 34% 91% Marwick [29] Tml 463 44 35% 93% All events 17% 98% Hard events McCully [30] Tml 1325 36 -97% Normal studies Syed [31] Tml 1325 36 17% 98% Includes revascularization Mazeika [32] Dob 51 24 68% 77% High risk Afridi [33] Dob 77 10 50% 87% Poldermans [34] Dob 430 17 26% 87% Kamaran [35] Dob 210 16 43% 92% Marcovitz [36] Dob 291 15 10-17% 99% Schroder [37] Dob 134 19 31% 94% Steinberg [38] Dob 120 60 67% 67% All events 13% 95% Hard events Senior [39] Dob 121 15 45% 88% Chuah [40] Dob 860 52 14% 96% Davar [41] Dob 72 F 13 -100% Normal studies Poldermans [42] Dob 1659 36 8-20% 96% Hard events Picano [43] Dip (hd) 539 36 26% 94% Dip (ld) 539 36 41% 94% Schroder [37] Dip 134 [42] . ( ) Normal; ( ) mild; ( ) >Mod. Figure 4 . Relationship of defect size (normal, mild, moderate and severe) with cardiac mortality in medically treated and revascularized patients [44] . ( ) Medical Rx; ( ) revascularized.
has been shown to be low, and does not justify intervention. Indeed, this group contributes to the low predictive value of a positive test. While data obtained with stress echocardiography has shown outcome to be related to the extent and severity of abnormal wall motion, ischaemic threshold may be assessed with pharmacological and bicycle stress echocardiography. This parameter is equivalent to heart-rate at the onset of ST segment depression, and indicates particularly vulnerable tissue; patients developing ischaemia at a low heart rate or smaller dose of pharmacological stress agent are more likely to have events than those in whom ischaemia is induced only at peak stress [46] .
Incremental Value of Stress Imaging Data
The cost of stress echocardiography or other stress imaging tests could be questioned if the data merely duplicated information already available from other tests. The strongest source of prognostic information during exercise testing is exercise capacity. Still, whether individuals exercise to high or low workloads, the presence of ischaemia still significantly influences adverse outcome [29] . Indeed, when statistical models for the prediction of cardiac events are developed, comprising initially clinical exercise testing and finally stress imaging data, the addition of imaging significantly improves the power of the model (Fig. 1) .
Discussions regarding the under-utilization of standard exercise testing compared with stress imaging processes often neglect the fact that an imaging test is required in the many patients undergoing stress testing because of inability to exercise or a non-diagnostic ECG. The remaining 30% of patients pose a common conundrum. Although it is known that the stress imaging approaches are more accurate and prognostically more powerful than stress imaging alone, these features are gained at significant increment of expense. In the diagnostic scenario, tests should be selected with the appropriate likelihood ratio to move the patient from an intermediate to high or low probability of coronary disease, taking into account the prevalence of disease and the pre-test probability in the individual patient. In the prognostic arena it may be worthwhile to consider a comparable approach based upon the probability of an adverse outcome on the grounds of clinical assessment and standard exercise testing, quantified by the Duke treadmill score [47] . Thus, while SPECT has been shown to identify higher risk groups even in individuals who have a low Duke treadmill score, this absolute risk remains low, and it is difficult to justify intervention in such individuals (Fig. 3) . On the other hand, high risk Duke treadmill scores confer a serious adverse event rate of >8% per year even if SPECT scan results are normal -although SPECT is further able to stratify this risk, an argument for aggressive evaluation and intervention could easily be made for such patients. The major benefit of a stress imaging approach is in individuals with an intermediate score, among whom annual event rates range from <2% with a normal SPECT, through 6% with a mild SPECT defect, to 9% with a moderate or greater size defect. No equivalent data have been reported with stress echocardiography, but similar findings might be anticipated.
Observational Studies of Outcome and Cost
As discussed above, computer models have predicted that selective use of stress imaging strategies is costeffective for diagnostic purposes. A more detailed computer model of cost-effectiveness of diagnostic strategies for chest pain (clinical evaluation, exercise ECG, exercise echocardiography, exercise SPECT, and coronary angiography) has recently been reported by Kuntz [48] . In middle-aged men with typical angina, the incremental cost-effectiveness ratio of coronary angiography compared with exercise echocardiography was $36 400 per quality-adjusted life-year (QALY) saved. In similar patients with atypical angina, exercise echocardiography compared with exercise ECG cost $41 900 per QALY saved, and exercise SPECT cost $54 800 per QALY saved. In similar patients with non-specific chest pain, the incremental cost-effectiveness ratio of exercise ECG compared with no testing was $57 700 per QALY saved. The authors concluded that exercise ECG or exercise echocardiography resulted in sensible costeffectiveness ratios for patients at mild to moderate risk for coronary artery disease, and that direct coronary angiography resulted in reasonable cost-effectiveness ratios for patients with a high pretest probability of disease. There remains a dearth of clinical data regarding the use of prognostic data to guide therapy. Two recent observational studies of cost-effectiveness have been reported from the nuclear literature, and may be a worthwhile model for similar studies with stress echocardiography. The group at Cedars Sinai Medical Center have examined the prognostic implications and costs of SPECT imaging in individuals at various levels of disease probability [45] . While SPECT testing conferred the greatest balance between the performance of angiography and number of events in intermediate risk patients (and therefore the cost per hard event saved was least in this group), an approach of indiscriminate angiography for a positive test led to unacceptably high costs (Table  7) . Taking into account the much lower probability of events in individuals with mild perfusion defects, the authors recommended that angiography be performed in those with moderate or larger defects, permitting a substantial reduction of cost without an unacceptable increase of missed events.
The largest cost-effectiveness study performed to date for stress imaging was the END study, in which 11 372 patients were examined at seven sites [49] . Approximately half underwent direct angiography and half underwent myocardial perfusion imaging and selective angiography. Costs were assessed from Medicare billing and follow-up was performed over an average of 2·5 years. The event rate in individuals at low, intermediate and high risk of events (based upon the Duke score) were all comparable. However, revascularization was much more frequently performed in patients at intermediate to high risk when an angiogram had been performed for diagnosis than when a SPECT test had been performed. This suggests that many individuals with anatomically significant but functionally mild coronary disease proceeded to coronary intervention. The direct consequence of this was that the diagnostic and follow-up costs of patients in the direct angiography group was almost twice that of those in the selective angiography group (Fig. 5) .
Conclusion
The last decade has brought unprecedented developments in the accuracy of diagnostic testing in general and echocardiography in particular. New advances such as contrast echocardiography and tissue Doppler promise to improve the feasibility and reproducibility of stress echocardiography. Nonetheless, the test is approximately three times as costly as a standard exercise test, reflecting the involvement of expensive equipment, a sonographer and an expert echocardiographer. Undoubtedly, the test is more accurate and prognostically more powerful than the standard stress test. What we now know is that the test may save money compared with other diagnostic strategies, for similar diagnostic accuracy. However, to remain competitive with nuclear imaging, further justification for its cost needs to be provided, based upon the ability to patient outcomes and thereby rationalize treatment choices. In all risk groups, both measures of cost were lower with a non-invasive strategy, but outcomes were comparable [46] . ( ) Diagnostic cost; ( ) follow-up cost.
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